Clinical Trial Update: Phase II Panitumumab-IRDye800 in Head & Neck Cancer [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase II study evaluating the Panitumumab-IRDye800 imaging agent for head and neck cancer, with recruitment currently ong…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Panitumumab-IRDye800

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Head and Neck Cancer | Phase 2 | Status: RECRUITING